PLANET GREEN HOLDINGS CORP Revenue 2010-2022 | PLAG

PLANET GREEN HOLDINGS CORP revenue from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
PLANET GREEN HOLDINGS CORP Annual Revenue
(Millions of US $)
2021 $38
2020 $4
2019 $1
2018 $7
2017 $5
2016 $80
2015 $141
2014 $218
2013 $215
2012 $240
2011 $213
2010 $184
2009 $147
PLANET GREEN HOLDINGS CORP Quarterly Revenue
(Millions of US $)
2022-03-31 $12
2021-12-31 $22
2021-09-30 $8
2021-06-30 $5
2021-03-31 $2
2020-12-31 $1
2020-09-30 $1
2020-06-30 $0
2020-03-31 $1
2019-12-31 $-1
2019-09-30 $0
2019-06-30 $1
2019-03-31 $1
2018-12-31 $4
2018-09-30 $1
2018-06-30 $1
2018-03-31 $1
2017-12-31 $1
2017-09-30 $1
2017-06-30 $1
2017-03-31 $2
2016-12-31 $6
2016-09-30 $28
2016-06-30 $23
2016-03-31 $22
2015-12-31 $20
2015-09-30 $48
2015-06-30 $36
2015-03-31 $38
2014-12-31 $98
2014-09-30 $55
2014-06-30 $33
2014-03-31 $32
2013-12-31 $93
2013-09-30 $53
2013-06-30 $34
2013-03-31 $35
2012-12-31 $104
2012-09-30 $58
2012-06-30 $41
2012-03-31 $37
2011-12-31 $91
2011-09-30 $56
2011-06-30 $36
2011-03-31 $30
2010-12-31 $82
2010-09-30 $48
2010-06-30 $29
2010-03-31 $25
2009-12-31 $63
2009-09-30 $39
2009-06-30 $24
2009-03-31 $21
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.024B $0.038B
Planet Green Holdings Corp is a biotechnology enterprise. It provides artificial intelligence integrates extraction, R&D, production and sales from natural plants. Planet Green Holdings Corp., formerly known as American Lorain Corporation, is based in China.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.981B 9.98
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
Biohaven Pharmaceutical Holding (BHVN) United States $9.996B 0.00
QIAGEN (QGEN) Netherlands $9.982B 15.76
Ginkgo Bioworks Holdings (DNA) United States $4.276B 0.00
Emergent Biosolutions (EBS) United States $1.424B 6.09
Arcus Biosciences (RCUS) United States $1.353B 34.31
Myovant Sciences (MYOV) United Kingdom $0.930B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.444B 0.00
Gelesis Holdings (GLS) United States $0.355B 0.00
Zymeworks (ZYME) Canada $0.299B 0.00
Ambrx Biopharma (AMAM) United States $0.138B 0.00
Enzo Biochem (ENZ) United States $0.118B 24.20
SQZ Biotechnologies (SQZ) United States $0.090B 0.00